Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients

European Respiratory Journal

Volumn 37, Issue 4, 2011, Pages 888-894

  Mathe C ^a   Bohacs A ^a   Duffek, L ^a   Lukacsovits J ^a   Komlosi, Z I ^a   Szondy, K ^a   Horvath I ^a   Muller V ^a   Losonczy, G ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Ageing kidney; Cardiovascular disease; Cisplatin nephrotoxicity; Diabetes mellitus; Lung cancer

Indexed keywords

CISPLATIN;

ADULT; AGING; ARTICLE; COMORBIDITY; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

AGING; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; CISPLATIN; CREATININE; DIABETES COMPLICATIONS; FEMALE; GLOMERULAR FILTRATION RATE; HEART; HUMANS; ISCHEMIA; KIDNEY; LIVER FUNCTION TESTS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TECHNETIUM TC 99M PENTETATE;

EID: 79953684340     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00055110     Document Type: Article

References (42)

1. Langerak AD, Dreisbach LD. Chemotherapy Regimens in Cancer Care. Georgetown, Landes Bioscience, 2001.
2. O'Dwyer PJ, Stevenson JP, Johnson SW. Clinical status of cisplatin, carboplatin and other platinum-based antitumor drugs. In: Lippert B, ed. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. Zurich, Wiley-VCH, 1999; pp. 29-70.
3. Gonzales-Vitale JC, Hayes DM, Cvitkovic E, et al. The renal pathology in clinical trials of cisplatinum (II) diamminedichloride. Cancer 1977; 39: 1362-1371. (Pubitemid 8108286)
4. Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormalplatin. Gynecol Oncol 1993; 50: 147-158. (Pubitemid 23275196)
5. Mayer KB, Madias NE. Cisplatin nephrotoxicity. Mineral Electrolyte Metab 1994; 20: 201-213. (Pubitemid 24320004)
6. Berns JS, Ford PA. Renal toxicities of antineoplastic drugs and bone marrow transplantation. Semin Nephrol 1997; 17: 54-66. (Pubitemid 27045162)
7. De Jongh FE, Van Veen RN, Veltman SJ, et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 2003; 88: 1199-1206. (Pubitemid 36606333)
8. Schottenfeld D. Epidemiology of lung cancer. In: Pass HI, Mitchell JB, Johnson DH, et al, eds. Lung Cancer. Principles and Practice. Philadelphia, Lippincott-Raven Publishers, 1996; pp. 305-321.
9. Silva FG. The aging kidney: a review - part I. Int Urol Nephrol 2005; 37: 185-205. (Pubitemid 41236267)
10. Hilton PJ, Lavender S, Roth Z, et al. Creatinine clearance in patients with proteinuria. Lancet 1969; 2: 1215-1216.
11. Launay-Vacher V, Etessami R, Janus N, et al. Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung 2009; 187: 69-74.
12. Cockcroft D, Gault MK. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
13. Launay-Vacher V, Chatelut E, Lichtman SM, et al. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 2007; 18: 1314-1321. (Pubitemid 47305003)
14. Schmidt RJ, Beierwaltes WH, Baylis C. Effects of aging and alterations in dietary sodium intake on total nitric oxide production. Am J Kidney Dis 2001; 37: 900-908. (Pubitemid 32436560)
15. Faubert PF, Porush JG. Anatomy and physiology. In: Faubert PF, Porush JG, eds. Renal Disease in the Elderly. 2nd Edn. New York, Marcel Dekker, Inc., 1998; pp. 7-10.
16. Lindeman RD, Godman R. Anatomic and physiologic age changes in the kidney. Exp Gerontol 1986; 21: 379-406. (Pubitemid 17215629)
17. Greenfeld Z, Baylis C. Aging and the renal circulation. In: E. Bittar, ed. Advances in Organ Biology. Vol. 9. Stamford, JAI Press, 2000; pp. 255-274.
18. Takazakura E, Sawabu N, Handa A, et al. Intrarenal vascular changes with age and disease. Kidney Int 1972; 2: 224-230.
19. Baylis C. Age-dependent glomerular damage in the rat: dissociation between glomerular injury and both glomerular hypertension and hypertrophy. J Clin Invest 1994; 94: 1823-1829.
20. Mune M, Otani H, Yukawa S. Effects of antioxidants on kidney disease. Mech Aging Dev 2002; 123: 1041-1046. (Pubitemid 34603087)
21. Bendayan M. Immunocytochemical detection of advance glycated end products in rat renal tissue as a function of age and diabetes. Kidney Int 1998; 54: 438-447. (Pubitemid 28357406)
22. Hamelin M, Borot-Laloi C, Friguet B, et al. Increased level of glycoxidation product Ne-(carboxymethyl) lysine in rat serum and urine proteins with aging: link with glycoxidative damage accumulation in kidney. Arch Biochem Biophys 2003; 411: 215-222. (Pubitemid 36298649)
23. Hill GS. Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens 2008; 17: 266-270. (Pubitemid 351535929)
24. Perkins BA, Krolewski AS. Early nephropathy in type 1 diabetes: the importance of eatrly renal function decline. Curr Opin Nephrol Hypertens 2009; 18: 233-240.
25. Hernandez-Marco R, Codoner-Franch P, Morales SP, et al. Oxidant/antioxidant status and hyperfiltration in young patients with type 1 diabetes mellitus. Pediatr Nephrol 2009; 24: 121-127.
26. Ohta Y, Fijii K, Arima H, et al. Increased renal resistive index in atherosclerosis and diabetic nephropathy assessed by Doppler sonography. J Hypertens 2005; 23: 1905-1911. (Pubitemid 41830431)
27. Fine LG, Orphanides G, Norman JT. Progressive renal disease: the chronic hypoxia hypothesis. Kidney Int Suppl 1998; 65: S74-S78. (Pubitemid 28204569)
28. Yamamoto K, Shimokawa T, Yi H, et al. Aging accelerates endotoxin-induced thrombosis: increased responses of plasminogen activator inhibitor-1 and lipopolysaccharide signaling with aging. Am J Pathol 2002; 161: 1805-1814. (Pubitemid 35265538)
29. Yamamoto K, Loskutoff DJ, Saito H. Renal expression of fibrinolytic genes and tissue factor in a murine model of renal disease as a function of age. Semin Thromb Haemost 1998; 24: 261-268. (Pubitemid 28345736)
30. Ali BH, Al Moundhri MS. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 2006; 44: 1173-1183.
31. Schuchter LM. Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethiol). Eur J Cancer 1996; 32: Suppl. 4, S40-S42.
32. Ramnath M, LoRusso P, Simon M, et al. Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer. Am J Clin Oncol 1997; 20: 368-372. (Pubitemid 27329569)
33. Anand AJ, Bashey B. Newer insights into cisplatin nephrotoxicity. Ann Pharmacother 1993; 27: 1519-1525. (Pubitemid 24005154)
34. Portilla D, Safar AM, Shannon MI, et al. Cisplatin nephrotoxicity. www.uptodate.com/cisplatin-nephrotoxicity. Date last accessed: January 7, 2011. Date last updated: January 1, 2010.
35. Al-Surraf M, Fletcher W, Oishi N, et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a Southwest Oncology Group study. Cancer Treat Rep 1982; 66: 31-35. (Pubitemid 12254661)
36. Mannel RS, Stratton JA, Moran G, et al. Intraperitoneal cisplatin: comparison of antitumor activity and toxicity as a function of solvent saline concentration. Gynecol Oncol 1989; 34: 50-53. (Pubitemid 19187961)
37. Kraibi AA, Knox FG. Control of sodium excretion. In: Massry SG, Glassock RJ, eds. Textbook of Nephrology. Baltimore, Williams & Wilkins, 1989; pp. 237-246.
38. Ozols RF, Corden BJ, Jacob J, et al. High-dose cisplatin in hypertonic saline. Ann Intern Med 1984; 100: 19-24. (Pubitemid 14219123)
39. Townsend DM, HaniganMH. Inhibition of c-glutamyl transpeptidase or cysteine S-conjugate b-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exp Ther 2002; 300: 142-148. (Pubitemid 34028520)
40. Hässner K, Rote-Liste-Secretary. Rote Liste. Berlin, Hartmann & Heinemann, 1998; pp. 52-251.
41. Hanigan MH, Deng M, Zhang L, et al. Stress response inhibits the nephrotoxicity of cisplatin. Am J Physiol Renal Physiol 2005; 288: F125-F132. (Pubitemid 40038684)
42. Launay-Vacher V, Rey J-B, Isnard-Bagnis C, et al. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 2008; 61: 903-909.